Child and Adolescent Immunization Schedule Vocabulary (2025)

Key terms, combination vaccine names, reporting systems, and clinical abbreviations from the 2025 Recommended Child and Adolescent Immunization Schedule.

Nirsevimab (Beyfortus)

Respiratory syncytial virus monoclonal antibody (RSV-mAb) recommended for prevention of RSV disease in infants and young children.

Vaxelis

Trade name for the combination DTaP, inactivated poliovirus, Haemophilus influenzae type b, and hepatitis B vaccine (DTaP-IPV-Hib-HepB).

ProQuad

Trade name for the combination measles, mumps, rubella, and varicella vaccine (MMRV).

Pediarix

Trade name for the combination DTaP, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV).

Pentacel

Trade name for the combination DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine (DTaP-IPV/Hib).

VAERS

Vaccine Adverse Event Reporting System; the system used to report clinically significant adverse events following vaccination.

VICP

National Vaccine Injury Compensation Program; a no-fault alternative to the traditional legal system for resolving vaccine injury claims, covering schedule vaccines except dengue, PPSV23, RSV, Mpox, and COVID-19.

CICP

Countermeasures Injury Compensation Program; the program covering vaccine injury claims for Mpox and COVID-19 vaccines.

Shared Clinical Decision-Making

Individually based vaccination recommendations informed by a decision process between the health care provider and the patient or parent/guardian.

Penbraya

Trade name for the meningococcal serogroups A, B, C, W, Y combination vaccine (MenACWY-TT/MenB-FHbp).

Abrysvo

Trade name for the respiratory syncytial virus vaccine (RSV) recommended for seasonal administration during pregnancy.

SCID

Severe Combined Immunodeficiency; an absolute contraindication for the administration of rotavirus (RV1, RV5) vaccines.

Penmenvy

Trade name for GSK's MenABCWY vaccine (MenACWY-CRM/MenB-4C) recommended when both MenACWY and MenB are indicated at the same clinic visit.